Plain-English translation of NCT06783816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a novel CAR-T cell therapy with IL-15 expression, a new type of treatment that uses your own immune cells to fight blood cancers. The therapy is designed for patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma, or multiple myeloma that has come back or stopped responding to standard chemotherapy. Researchers want to see how safe and effective this treatment is, and how long the immune cells survive and work in your body.
Blood cancers like leukemia, lymphoma, and multiple myeloma can be difficult to treat once they return or become resistant to chemotherapy. This new treatment aims to give patients whose cancers no longer respond to standard options a potentially more powerful way to fight their disease by enhancing their own immune system's ability to destroy cancer cells.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the study, you will receive the new immune cell treatment through an infusion, with doses tailored to your body weight and the type of cancer you have. You will be monitored closely with regular clinic visits, blood tests, and imaging scans to check how well the treatment is working and watch for any side effects. The study will track how your immune cells survive and function in your body over time, with follow-up care continuing for several months after your initial treatment.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Sponsor
Shanxi Bethune Hospital
Enrollment target
~45 participants
Started
December 2023
Primary completion
June 2028
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
JIA WEI
Shanxi Bethune Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.